Top-Rated StocksTop-RatedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Forecast, Price & News $125.91 -1.99 (-1.56%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$125.79▼$129.0850-Day Range$120.20▼$157.1952-Week Range$61.28▼$159.89Volume502,760 shsAverage Volume1.48 million shsMarket Capitalization$11.73 billionP/E RatioN/ADividend YieldN/APrice Target$168.76 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sarepta Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.94 Rating ScoreUpside/Downside34.0% Upside$168.76 Price TargetShort InterestHealthy4.03% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.38Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.88) to $1.84 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector48th out of 986 stocksPharmaceutical Preparations Industry18th out of 473 stocks 4.5 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $168.76, Sarepta Therapeutics has a forecasted upside of 34.0% from its current price of $125.91.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.03% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 8.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 1.9 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Sarepta Therapeutics this week, compared to 8 articles on an average week.Search Interest38 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions87.31% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($10.88) to $1.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 28.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sarepta Therapeutics (NASDAQ:SRPT) StockSarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.Read More Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock News HeadlinesMay 18, 2023 | marketbeat.comAnalysts Say These 2 Mid-Cap Biotechs Have 2x Potential (SRPT)These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.May 16, 2023 | marketbeat.comSarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy (SRPT)Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.June 8, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.June 8, 2023 | finance.yahoo.comMirati (MRTX) Down 17.6% Since Last Earnings Report: Can It Rebound?June 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Healthequity (HQY), NovoCure (NVCR) and Sarepta Therapeutics (SRPT)June 6, 2023 | msn.comRBC Capital Reiterates Sarepta Therapeutics (SRPT) Outperform RecommendationJune 6, 2023 | msn.com24 Analysts Have This to Say About Sarepta TherapeuticsJune 1, 2023 | finance.yahoo.comWhy Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?June 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!June 1, 2023 | msn.comIs Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?May 30, 2023 | msn.comEvercore ISI Group Maintains Sarepta Therapeutics (SRPT) Outperform RecommendationMay 30, 2023 | americanbankingnews.comEvercore ISI Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $151.00May 30, 2023 | americanbankingnews.comWilliam Blair Comments on Sarepta Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:SRPT)May 27, 2023 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) PT Lowered to $141.00May 26, 2023 | msn.comOppenheimer Reiterates Sarepta Therapeutics (SRPT) Outperform RecommendationMay 26, 2023 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down on Analyst DowngradeMay 24, 2023 | msn.comSarepta Tumbles as FDA Delays Duchenne Gene Therapy DecisionMay 24, 2023 | markets.businessinsider.comSarepta Therapeutics Updates Of BLA For Sarepta's Duchenne Muscular Dystrophy Drug CandidateMay 24, 2023 | msn.comSarepta Plunges as FDA Requires More Time for Drug ReviewMay 24, 2023 | finance.yahoo.comFDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of WeeksMay 24, 2023 | finance.yahoo.comSarepta Therapeutics Dives On An Unexpected Holdup For Its Gene TherapyMay 24, 2023 | finance.yahoo.comWhy Shares of Sarepta Therapeutics Are Dropping WednesdayMay 24, 2023 | reuters.comFDA defers decision for Sarepta's gene therapy to June 22 from May 29May 24, 2023 | msn.comSarepta says FDA needs more time to review muscular dystrophy drugMay 24, 2023 | finance.yahoo.comSarepta Therapeutics Announces Update on Regulatory Review of SRP-9001May 24, 2023 | finance.yahoo.comUPDATE 2-FDA defers decision for Sarepta's gene therapy to June 22 from May 29May 23, 2023 | seekingalpha.comBuy Sarepta Therapeutics For A Likely Positive FDA Decision DateSee More Headlines SRPT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Company Calendar Last Earnings5/02/2023Today6/08/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,162Year Founded1980Price Target and Rating Average Stock Price Forecast$168.76 High Stock Price Forecast$218.00 Low Stock Price Forecast$122.00 Forecasted Upside/Downside+34.0%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($12.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-703,490,000.00 Net Margins-114.30% Pretax Margin-112.59% Return on Equity-128.64% Return on Assets-23.50% Debt Debt-to-Equity Ratio1.73 Current Ratio4.63 Quick Ratio4.26 Sales & Book Value Annual Sales$933.01 million Price / Sales12.57 Cash FlowN/A Price / Cash FlowN/A Book Value$4.39 per share Price / Book28.68Miscellaneous Outstanding Shares93,150,000Free Float86,256,000Market Cap$11.73 billion OptionableOptionable Beta1.01 Social Links Key ExecutivesDouglas S. IngramPresident, Chief Executive Officer & DirectorIan M. EstepanExecutive VP, Chief Financial & Accounting OfficerLouise Rodino-KlapacChief Scientific Officer & Executive VPBilal ArifChief Technical Operations Officer & Executive VPDiane BerryEVP, Chief Global Policy & Advocacy OfficerKey CompetitorsViatrisNASDAQ:VTRSLegend BiotechNASDAQ:LEGNApellis PharmaceuticalsNASDAQ:APLSUnited TherapeuticsNASDAQ:UTHRPrometheus BiosciencesNASDAQ:RXDXView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 522 shares on 6/1/2023Ownership: 0.028%Prelude Capital Management LLCBought 3,501 shares on 6/1/2023Ownership: 0.004%ProShare Advisors LLCSold 2,491 shares on 5/26/2023Ownership: 0.007%Ameriprise Financial Inc.Sold 14,849,252 shares on 5/22/2023Ownership: 0.804%New York State Common Retirement FundSold 4,467 shares on 5/18/2023Ownership: 0.093%View All Insider TransactionsView All Institutional Transactions SRPT Stock - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price forecast for 2023? 16 equities research analysts have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $122.00 to $218.00. On average, they predict the company's stock price to reach $168.76 in the next year. This suggests a possible upside of 34.0% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2023? Sarepta Therapeutics' stock was trading at $129.58 at the start of the year. Since then, SRPT shares have decreased by 2.8% and is now trading at $125.91. View the best growth stocks for 2023 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.46) by $0.49. The biotechnology company had revenue of $253.50 million for the quarter, compared to analysts' expectations of $241.47 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 128.64% and a negative net margin of 114.30%. The business's quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.20) earnings per share. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), American Century Mid Cap Growth Impact (MID), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Franklin Genomic Advancements ETF (HELX). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). What is Sarepta Therapeutics' stock symbol? Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT." Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.67%), Wellington Management Group LLP (3.15%), Bank of New York Mellon Corp (2.06%), State Street Corp (1.90%), Geode Capital Management LLC (1.35%) and Pictet Asset Management SA (1.30%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sarepta Therapeutics' stock price today? One share of SRPT stock can currently be purchased for approximately $125.91. How much money does Sarepta Therapeutics make? Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $11.73 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($12.69) on an earnings per share basis. How many employees does Sarepta Therapeutics have? The company employs 1,162 workers across the globe. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More How can I contact Sarepta Therapeutics? Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038. This page (NASDAQ:SRPT) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.